Man Group
SUPN icon

Man Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Man Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.28M Buy
156,422
+81,430
+109% +$3.91M 0.01% 944
2026
Q1 		$3.88M Buy
74,992
+43,895
+141% +$2.24M 0.01% 1282
2025
Q4 		$1.55M Sell
31,097
-63,984
-67% -$3.11M ﹤0.01% 1547
2025
Q3 		$4.54M Buy
95,081
+30,337
+47% +$1.22M 0.01% 1114
2025
Q2 		$2.04M Buy
64,744
+24,123
+59% +$773K ﹤0.01% 1410
2025
Q1 		$1.33M Buy
40,621
+17,057
+72% +$604K ﹤0.01% 1507
2024
Q4 		$852K Sell
23,564
-760
-3% -$26.8K ﹤0.01% 1534
2024
Q3 		$758K Buy
+24,324
New +$759K ﹤0.01% 1561
2023
Q3 		– Sell
-60,462
Closed -$1.84M – 1633
2023
Q2 		$1.82M Buy
+60,462
New +$2.12M 0.01% 1234
2023
Q1 		– Sell
-40,765
Closed -$1.57M – 1234
2022
Q4 		$1.45M Buy
+40,765
New +$1.42M 0.01% 1211
2021
Q2 		– Sell
-10,900
Closed -$285K – 2094
2021
Q1 		$285K Sell
10,900
-191,628
-95% -$5.36M ﹤0.01% 1641
2020
Q4 		$5.1M Sell
202,528
-50,800
-20% -$1.09M 0.02% 799
2020
Q3 		$5.28M Buy
253,328
+64,655
+34% +$1.47M 0.02% 784
2020
Q2 		$4.48M Buy
188,673
+62,582
+50% +$1.38M 0.02% 725
2020
Q1 		$2.27M Buy
126,091
+9,075
+8% +$191K 0.01% 835
2019
Q4 		$2.77M Buy
117,016
+60,225
+106% +$1.46M 0.01% 1225
2019
Q3 		$1.56M Buy
56,791
+16,411
+41% +$486K 0.01% 1323
2019
Q2 		$1.34M Sell
40,380
-97,077
-71% -$3.33M ﹤0.01% 1443
2019
Q1 		$4.82M Buy
137,457
+131,109
+2,065% +$4.88M 0.02% 944
2018
Q4 		$211K Sell
6,348
-107,662
-94% -$4.63M ﹤0.01% 1805
2018
Q3 		$5.74M Sell
114,010
-54,142
-32% -$2.67M 0.02% 919
2018
Q2 		$10.1M Sell
168,152
-65,062
-28% -$3.37M 0.04% 583
2018
Q1 		$10.7M Buy
+233,214
New +$9.73M 0.05% 457

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Man Group's SUPN Position: Q2 2026 in Review

Man Group increased its Supernus Pharmaceuticals (SUPN) stake by 109% in Q2 2026, buying an estimated $3.91M and bringing the position to 156,422 shares worth $7.28M. The position accounts for 0.01% of the portfolio, ranked #944.

Man Group first reported a position in SUPN in Q1 2018 and has held it in 23 quarters since. The position peaked at $10.7M in Q1 2018. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Man Group held 156,422 shares of Supernus Pharmaceuticals worth $7.28M as of Q2 2026.
  • Man Group bought 81,430 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.91M.
  • Supernus Pharmaceuticals made up 0.01% of Man Group's portfolio in Q2 2026, its #944 holding.
  • Man Group first reported a position in Supernus Pharmaceuticals in Q1 2018 and has held it in 23 quarters since.
  • Man Group's Supernus Pharmaceuticals position peaked at $10.7M in Q1 2018.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.